Notes
The study was funded by Celgene, a Bristol-Myers Squibb Company.
Reference
Bonafede M, et al. Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis. PharmacoEconomics-Open : 13 Oct 2020. Available from: URL: https://doi.org/10.1007/s41669-020-00233-8
Rights and permissions
About this article
Cite this article
Assessing indirect cost burden of employed MS patients on DMT in US. PharmacoEcon Outcomes News 865, 4 (2020). https://doi.org/10.1007/s40274-020-7228-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7228-0